Arovella Therapeutics Management
Management criteria checks 1/4
Arovella Therapeutics' CEO is Michael Baker, appointed in Jan 2020, has a tenure of 4.92 years. total yearly compensation is A$558.31K, comprised of 60.9% salary and 39.1% bonuses, including company stock and options. directly owns 0.62% of the company’s shares, worth A$1.12M. The average tenure of the management team and the board of directors is 1.6 years and 2.8 years respectively.
Key information
Michael Baker
Chief executive officer
AU$558.3k
Total compensation
| CEO salary percentage | 60.9% |
| CEO tenure | 4.9yrs |
| CEO ownership | 0.6% |
| Management average tenure | 1.6yrs |
| Board average tenure | 2.8yrs |
Recent management updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | AU$558k | AU$340k | -AU$9m |
| Mar 31 2024 | n/a | n/a | -AU$9m |
| Dec 31 2023 | n/a | n/a | -AU$10m |
| Sep 30 2023 | n/a | n/a | -AU$10m |
| Jun 30 2023 | AU$528k | AU$325k | -AU$10m |
| Mar 31 2023 | n/a | n/a | -AU$9m |
| Dec 31 2022 | n/a | n/a | -AU$9m |
| Sep 30 2022 | n/a | n/a | -AU$9m |
| Jun 30 2022 | AU$604k | AU$303k | -AU$9m |
| Mar 31 2022 | n/a | n/a | -AU$8m |
| Dec 31 2021 | n/a | n/a | -AU$7m |
| Sep 30 2021 | n/a | n/a | -AU$6m |
| Jun 30 2021 | AU$403k | AU$275k | -AU$5m |
| Mar 31 2021 | n/a | n/a | -AU$5m |
| Dec 31 2020 | n/a | n/a | AU$2m |
| Sep 30 2020 | n/a | n/a | -AU$1m |
| Jun 30 2020 | AU$385k | AU$124k | -AU$4m |
Compensation vs Market: Michael's total compensation ($USD348.44K) is about average for companies of similar size in the Australian market ($USD288.21K).
Compensation vs Earnings: Michael's compensation has increased whilst the company is unprofitable.
CEO
Michael Baker
4.9yrs
Tenure
AU$558,311
Compensation
Dr. Michael Baker serves as Chief Executive Officer of Arovella Therapeutics Limited (formerly known as Suda Pharmaceuticals Ltd). since January 2, 2020 and served as its Executive Chairman until July 1, 2...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, MD & Director | 4.9yrs | AU$558.31k | 0.62% A$ 1.1m | |
| Chief Operating Officer | 1.9yrs | AU$423.15k | 0.078% A$ 139.8k | |
| Company Secretary & CFO | less than a year | no data | no data | |
| Administration Manager | 1.3yrs | no data | no data |
1.6yrs
Average Tenure
Experienced Management: ALA's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, MD & Director | 4.9yrs | AU$558.31k | 0.62% A$ 1.1m | |
| Independent Non-Executive Director | 2.4yrs | AU$84.38k | 0.074% A$ 134.1k | |
| Independent Non-Executive Director | 3.1yrs | AU$116.13k | 0.072% A$ 129.7k | |
| Non-Executive Chair | 1.8yrs | AU$332.53k | 0.45% A$ 807.1k | |
| Member of Clinical Advisory Board | less than a year | no data | no data | |
| Member of Scientific Advisory Board | less than a year | no data | no data | |
| Member of Clinical Advisory Board & Independent Non-Executive Director | 3.3yrs | AU$115.94k | 0.025% A$ 44.7k | |
| Member of Scientific Advisory Board | 3.3yrs | no data | no data | |
| Member of Scientific Advisory Board | 3.3yrs | no data | no data | |
| Chairman of Scientific Advisory Board | no data | no data | no data | |
| Chair of Clinical Advisory Board | less than a year | no data | no data |
2.8yrs
Average Tenure
63yo
Average Age
Experienced Board: ALA's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/30 04:53 |
| End of Day Share Price | 2024/12/30 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Arovella Therapeutics Limited is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Nidhi Singh | Edison Investment Research |
| Andrew Goodsall | MST Financial Services Pty Limited |